HHS agency warns hospitals nationwide not to ‘mutilate’ children
Caroline MolloyThe Centers for Medicare & Medicaid Services (CMS) – an agency of the Department of Health and Human Services (HHS) – announced Wednesday it is alerting hospital providers they are obligated to “protect American children from often irreversible chemical and surgical mutilation” that results from what the transgender medical industry calls “gender-affirming care.”
The agency’s press release comes following President Donald Trump’s executive order, issued January 28, that seeks to “protect children from chemical and surgical mutilation” and from those who make the “radical and false claim that adults can change a child’s sex through a series of irreversible medical interventions.”
In CMS’ special alert to hospitals, the agency confronts providers of the “dangerous chemical and surgical mutilation of children, including interventions that cause sterilization.”
“CMS is reminding providers of the program requirements of hospitals to serve all patients, especially children, with dignity and adherence to the highest standard of care that is informed by robust evidence and the utmost scientific integrity,” the alert continues.
However, due to the pro-transgender political agenda of the Biden-Harris administration over the past four years, the United States, CMS observes, is behind other nations that have come to accept the true science of biology.
“In recent years, medical interventions for gender dysphoria in children have proliferated,” the agency’s statement explains. “The U.S. is now an outlier in the treatment of gender dysphoria in children. The United Kingdom, Sweden, and Finland have recently issued restrictions on the medical interventions for children, including the use of puberty blockers and hormone treatments, and now recommend exploratory psychotherapy as a first line of treatment and reserve hormonal interventions only for exceptional cases.”
CMS takes special note of the UK’s Cass Review, a systematic examination of studies and guidelines led by British pediatrician Dr. Hilary Cass. The review team drew the conclusion that the “gender-affirming care” model of medical intervention for young people has been based on “remarkably weak evidence.”
The HHS agency reminds providers of the following evidence: “Around 85% of children with reported gender dysphoria—which includes more than 300,000 children between the ages of 13 and 17—do not suffer this condition throughout their adolescence. There is no reliable method by which the minority whose gender dysphoria will persist can be identified with confidence during childhood. However, thousands of children have received chemical or surgical interventions that, in many cases, are irreversible.”
